534 related articles for article (PubMed ID: 10963635)
21. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.
Wells PS; Forgie MA; Simms M; Greene A; Touchie D; Lewis G; Anderson J; Rodger MA
Arch Intern Med; 2003 Apr; 163(8):917-20. PubMed ID: 12719200
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
Louzada ML; Majeed H; Wells PS
Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
[TBL] [Abstract][Full Text] [Related]
23. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Levine MN; Raskob G; Beyth RJ; Kearon C; Schulman S
Chest; 2004 Sep; 126(3 Suppl):287S-310S. PubMed ID: 15383476
[TBL] [Abstract][Full Text] [Related]
24. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
25. Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism.
Svensson P; Södermark A; Schulman S
Hematol J; 2002; 3(6):311-4. PubMed ID: 12522454
[TBL] [Abstract][Full Text] [Related]
26. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy.
Palareti G; Legnani C; Lee A; Manotti C; Hirsh J; D'Angelo A; Pengo V; Moia M; Coccheri S
Thromb Haemost; 2000 Nov; 84(5):805-10. PubMed ID: 11127860
[TBL] [Abstract][Full Text] [Related]
27. Venous thromboembolism in centenarians: Findings from the RIETE registry.
Lacruz B; Tiberio G; Núñez MJ; López-Jiménez L; Riera-Mestre A; Tiraferri E; Verhamme P; Mazzolai L; González J; Monreal M;
Eur J Intern Med; 2016 Dec; 36():62-66. PubMed ID: 27495947
[TBL] [Abstract][Full Text] [Related]
28. Treatment of venous thromboembolism.
Eichinger S
Wien Med Wochenschr; 2005 Jan; 155(1-2):7-10. PubMed ID: 15773736
[TBL] [Abstract][Full Text] [Related]
29. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
30. Current management of acute symptomatic deep vein thrombosis.
Heit JA
Am J Cardiovasc Drugs; 2001; 1(1):45-50. PubMed ID: 14728051
[TBL] [Abstract][Full Text] [Related]
31. Recurrent venous thromboembolism in a Spanish population: incidence, risk factors, and management in a hospital setting.
Grau E; Real E; Medrano J; Pastor E; Selfa S
Thromb Res; 1999 Dec; 96(5):335-41. PubMed ID: 10605948
[TBL] [Abstract][Full Text] [Related]
32. Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
van Rein N; Biedermann JS; van der Meer FJM; Cannegieter SC; Wiersma N; Vermaas HW; Reitsma PH; Kruip MJHA; Lijfering WM
J Thromb Haemost; 2017 Jul; 15(7):1386-1391. PubMed ID: 28440008
[TBL] [Abstract][Full Text] [Related]
33. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.
Hull RD; Pineo GF; Brant RF; Mah AF; Burke N; Dear R; Wong T; Cook R; Solymoss S; Poon MC; Raskob G;
Am J Med; 2007 Jan; 120(1):72-82. PubMed ID: 17208082
[TBL] [Abstract][Full Text] [Related]
34. Extended prophylaxis of venous thromboembolism with idraparinux.
; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
N Engl J Med; 2007 Sep; 357(11):1105-12. PubMed ID: 17855671
[TBL] [Abstract][Full Text] [Related]
35. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Geerts WH; Pineo GF; Heit JA; Bergqvist D; Lassen MR; Colwell CW; Ray JG
Chest; 2004 Sep; 126(3 Suppl):338S-400S. PubMed ID: 15383478
[TBL] [Abstract][Full Text] [Related]
36. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism.
Hirsh J; Siragusa S; Cosmi B; Ginsberg JS
Thromb Haemost; 1995 Jul; 74(1):360-3. PubMed ID: 8578485
[TBL] [Abstract][Full Text] [Related]
37. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.
Hutten BA; Prins MH
Cochrane Database Syst Rev; 2000; (3):CD001367. PubMed ID: 10908494
[TBL] [Abstract][Full Text] [Related]
38. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
39. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
[TBL] [Abstract][Full Text] [Related]
40. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
